News & Updates

Oral anticoagulant therapy for acute VTE in obese patients

03 Apr 2023 by

Although direct-acting oral anticoagulants (DOACs) are widely recommended for first-line treatment of venous thromboembolism (VTE), their use in obese patients remains controversial due to the limited representation of such patients in clinical trials. As the prevalence of obesity continues its upward trend, clinicians increasingly have to make treatment decisions for obese patients. MIMS Doctor interviewed Adjunct Assistant Professor Pankaj Kumar Handa, Senior Consultant at Tan Tock Seng Hospital, Singapore, to gain his perspectives on oral anticoagulation in obese patients.

Oral anticoagulant therapy for acute VTE in obese patients

03 Apr 2023

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023 by

While current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with non-valvular atrial fibrillation (NVAF), there is a lack of head-to-head trial data to guide the choice of DOAC. Esteemed expert Dr Teo Wee Siong, Consultant Cardiologist & Cardiac Electrophysiologist from Mount Elizabeth Medical Centre, Singapore, reviewed the latest data on the comparative effectiveness and safety of DOACs in AF, provided valuable insights on considerations for the selection of DOACs, and shared his clinical experience with apixaban (Eliquis, Pfizer).

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

24 Jul 2022 by

Long-term anticoagulation therapy is often recommended for patients with atrial fibrillation (AF) to reduce their risk of stroke, but gastrointestinal bleeding (GIB) is a common complication that presents a significant challenge. Patients with a history of GIB have heightened risks of recurrent bleeding events, hence interruption or discontinuation of anticoagulants is often warranted. When and how to restart anticoagulant therapy following an episode of GIB has been debated. MIMS Doctor interviewed Dr Pipin Kojodjojo, Cardiologist and Cardiac Electrophysiologist at Asian Heart & Vascular Centre, Singapore, to gather his perspectives on how to manage anticoagulant therapy after a GIB episode.

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

24 Jul 2022

Challenging the status quo: The need for a new gastric acid suppressor

03 Jun 2020

For decades, the treatment of acid-related disorders have been limited to conventional acid suppressants. However, as Dr Daphne Ang (Changi General Hospital, Singapore) explains, clinicians can now maximise acid suppression through newer acid suppressants through potassium competitive inhibition.

Challenging the status quo: The need for a new gastric acid suppressor

03 Jun 2020

News & Updates

Filter by Specialty:

Specialty:

Oral anticoagulant therapy for acute VTE in obese patients

Oral anticoagulant therapy for acute VTE in obese patients

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

Challenging the status quo: The need for a new gastric acid suppressor

Challenging the status quo: The need for a new gastric acid suppressor